Paul B Chapman

Paul B Chapman

UNVERIFIED PROFILE

Are you Paul B Chapman?   Register this Author

Register author
Paul B Chapman

Paul B Chapman

Publications by authors named "Paul B Chapman"

Are you Paul B Chapman?   Register this Author

100Publications

9024Reads

7Profile Views

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Cancer Cell 2018 11 1;34(5):852-862.e4. Epub 2018 Nov 1.

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234065PMC
November 2018

Changing the standard of care for treating melanoma brain metastases.

Authors:
Paul B Chapman

Lancet Oncol 2018 05 27;19(5):589-591. Epub 2018 Mar 27.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30187-6DOI Listing
May 2018

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

J Clin Oncol 2018 04 12;36(12):1232-1239. Epub 2018 Mar 12.

Richard D. Carvajal and Gary K. Schwartz, Columbia University Medical Center; Paul B. Chapman and Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY; Sophie Piperno-Neumann and Manuel J. Rodrigues, Institut Curie, Paris; Lauris Gastaud, Centre Antoine-Lacassagne, Nice, France; Ellen Kapiteijn, Leiden University Medical Center, Leiden, the Netherlands; Stephen Frank, Hebrew University Hadassah Medical School - The Sharett Institute of Oncology, Jerusalem; Jacob Schachter, Sheba Medical Center at Tel Hashomer, and Tel-Aviv University Medical School, Tel Aviv, Israel; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Josep M. Piulats, Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Veronique Cocquyt, Ghent University Hospital, Ghent, Belgium; Bartosz Chmielowski, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; T.R. Jeffry Evans, University of Glasgow, Glasgow; Delyth Clemett, Shirley Spratt, Susan Lovick, and Elaine Kilgour, AstraZeneca, Macclesfield; Dana Ghiorghiu and Gabriella Mariani, AstraZeneca, Cambridge; Paul Nathan, Mt Vernon Cancer Centre, Northwood, United Kingdom; Gerald Linette, Washington University School of Medicine, St Louis, MO; Carola Berking, University Hospital of Munich, Munich, Germany; Peter Barker, AstraZeneca, Gaithersburg, MD; and Zhongwu Lai, AstraZeneca, Waltham, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.1090DOI Listing
April 2018

Time to publication of oncology trials and why some trials are never published.

PLoS One 2017 21;12(9):e0184025. Epub 2017 Sep 21.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184025PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608207PMC
October 2017

Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.

Ann Surg Oncol 2017 Apr 1;24(4):939-946. Epub 2016 Nov 1.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5642-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505631PMC
April 2017

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (CFF, VC, TB, ANS, PM, MKC, JDW, PBC, MDH, MAP); Weill Cornell Medical College, New York, NY (CFF, AVR, ANS, PM, MKC, JDW, PBC, MDH, MAP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441295PMC
April 2017

A step forward for patients with NRAS-mutant melanoma.

Lancet Oncol 2017 04 9;18(4):414-415. Epub 2017 Mar 9.

Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30172-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540131PMC
April 2017

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Melanoma Res 2017 02;27(1):57-64

aMelanoma and Immunotherapeutics Service, Department of Medicine bDepartment of Radiology cDepartment of Epidemiology and Biostatistics dDepartment of Surgery, Memorial Sloan Kettering Cancer Center eWeill Cornell Medical College fColumbia University Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553194PMC
February 2017

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.

Am J Dermatopathol 2016 Sep;38(9):687-9

*Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; †Memorial Sloan Kettering Cancer Center, New York, NY; and ‡George Washington University, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510737PMC
September 2016

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Melanoma Res 2016 06;26(3):272-7

aMelanoma and Immunotherapeutics Service bMolecular Imaging and Therapy Service cDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center dWeill Cornell Medical College eDivision of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553199PMC
June 2016

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Clin Cancer Res 2016 05 3;22(10):2323-8. Epub 2016 Feb 3.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502354PMC
May 2016

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Clin Cancer Res 2016 05;22(9):2114-20

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856220PMC
May 2016

Reply to A. Indini et al.

J Clin Oncol 2016 Mar 19;34(9):1018-9. Epub 2016 Jan 19.

Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7007DOI Listing
March 2016

Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.

Authors:
Paul B Chapman

Am Soc Clin Oncol Educ Book 2013

From the Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e80DOI Listing
December 2015

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.

Am Soc Clin Oncol Educ Book 2014 :e412-21

From the Memorial Sloan-Kettering Cancer Center, New York, NY; Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Department of Cutaneous Oncology, Moffitt Cancer Center, and Departments of Oncologic Sciences and Surgery, University of South Florida, Tampa, FL.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/11400412-144
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e412DOI Listing
December 2015

Osteonecrosis of the jaw a new complication related to Ipilimumab.

Oral Oncol 2015 Dec 5;51(12):e100-1. Epub 2015 Oct 5.

Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2015.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784100PMC
December 2015

Treating metastatic melanoma in 2014: what just happened and what is next?

Authors:
Paul B Chapman

Am Soc Clin Oncol Educ Book 2014 :16-9

From the Melanoma Section, Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.16DOI Listing
November 2015

Safety of Infusing Ipilimumab Over 30 Minutes.

J Clin Oncol 2015 Oct 29;33(30):3454-8. Epub 2015 Jun 29.

Parisa Momtaz, Vivian Park, Katherine S. Panageas, Michael A. Postow, Margaret Callahan, Jedd D. Wolchok, and Paul B. Chapman, Memorial Sloan-Kettering Cancer Center; Jedd D. Wolchok, Ludwig Institute for Cancer Research; and Michael A. Postow, Margaret Callahan, Jedd D. Wolchok, and Paul B. Chapman, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.0030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087314PMC
October 2015

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

J Clin Oncol 2015 Oct 17;33(28):3193-8. Epub 2015 Aug 17.

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang, Kaitlin M. Woo, Katherine S. Panageas, Parisa Momtaz, Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, and Paul B. Chapman, Memorial Sloan Kettering Cancer Center; Jedd D. Wolchok, Ludwig Institute for Cancer Research; and Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, and Paul B. Chapman, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087335PMC
October 2015

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Oncologist 2015 Jul 8;20(7):789-97. Epub 2015 May 8.

Departments of Medicine and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA; Human Oncology and Pathogenesis Program, Memorial Hospital Research Laboratories, New York, New York, USA; Immunology and Molecular and Pharmacology and Chemistry Programs, Sloan Kettering Institute, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492223PMC
July 2015

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Cancer J 2014 Jan-Feb;20(1):18-24

From the *Karmanos Cancer Center, Wayne State University, Detroit, MI; †The Angeles Clinic and Research Institute, Los Angeles, CA; ‡Washington University, St Louis, MO; §University of Pennsylvania, Philadelphia, PA; ∥Oncology Specialists S.C., Park Ridge, IL; ¶University of Colorado Cancer Center, Aurora, CO; #Baylor Sammons Cancer Center, Texas Oncology, PA, Dallas, TX; **NYU Medical Center, New York, NY; ††South Carolina Oncology Associates, Columbia, SC; ‡‡Providence Portland Medical Center, Portland, OR; §§Winship Cancer Institute, Emory University, Atlanta, GA; ∥∥Memorial Sloan Kettering Cancer Center, New York, NY; ¶¶Seattle Cancer Care Alliance, Seattle, WA; ##UCLA School of Medicine, Los Angeles, CA; ***Beth Israel Deaconess Medical Center and †††Massachusetts General Hospital, Boston, MA; ‡‡‡University of Arizona Cancer Center, Tucson, AZ; §§§Dana Farber Cancer Institute, Boston, MA; ∥∥∥Genentech, San Francisco, CA; ¶¶¶The SFJ Pharma Group, Pleasanton, CA; and ###Sarah Cannon Research Institute, Nashville, TN.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2014/01000/A_Single_
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705837PMC
May 2015

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

N Engl J Med 2015 May 20;372(21):2073-4. Epub 2015 Apr 20.

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1501894DOI Listing
May 2015

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.

Nat Commun 2015 Apr 29;6:6840. Epub 2015 Apr 29.

1] Children's Cancer and Blood Foundation Laboratories and Departments of Pediatrics and Cell and Developmental Biology, Weill Cornell Medical College, 413 East 69th Street, New York City, New York 10021, USA [2] Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York City, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms7840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423225PMC
April 2015

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Cancer Cell 2014 Nov 10;26(5):603-4. Epub 2014 Nov 10.

Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108140042
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2014.10.017DOI Listing
November 2014

Inflammatory metastatic melanoma presenting as a rash in the groin of an elderly woman.

J Dtsch Dermatol Ges 2014 Aug 1;12(8):726-7. Epub 2014 Jul 1.

Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.12327DOI Listing
August 2014

Entzündliches metastasiertes Melanom manifestiert sich als Exanthem in der Leiste einer älteren Frau.

J Dtsch Dermatol Ges 2014 Aug;12(8):726-728

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.12327_supplDOI Listing
August 2014

Opportunistic infections in patients treated with immunotherapy for cancer.

J Immunother Cancer 2014 18;2:19. Epub 2014 Jun 18.

Memorial Sloan-Kettering Cancer Center, Melanoma and Immunotherapeutics Oncology Service, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-1
Publisher Site
http://dx.doi.org/10.1186/2051-1426-2-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079190PMC
July 2014

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Cancer Discov 2014 May 3;4(5):538-45. Epub 2014 Mar 3.

1Human Oncology and Pathogenesis Program, 2Leukemia Service, 3Gastrointestinal Oncology Service, 4Melanoma and Immunotherapeutics Service, Department of Medicine, 5Molecular Diagnostics Service, Department of Pathology, 6Department of Radiology, 7Center for Molecular Oncology, 8Ludwig Center for Cancer Immunotherapy, and 9Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center; and 10Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850735PMC
May 2014

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Cancer Res 2014 Apr 27;74(8):2340-50. Epub 2014 Feb 27.

Authors' Affiliations: Louis V. Gerstner, Jr. Graduate School of Biomedical Science; Human Oncology and Pathogenesis Program; Departments of Pediatrics, Pathology, and Medicine; Programs in Molecular Pharmacology and Chemistry; Computational Biology; Ludwig Collaborative Lab, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Departments of Epidemiology and Biostatistics and Medicine, and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005042PMC
April 2014

Dynamic prognostication using conditional survival estimates.

Cancer 2013 Oct 1;119(20):3589-92. Epub 2013 Aug 1.

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28273DOI Listing
October 2013

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

N Engl J Med 2012 Dec 7;367(24):2316-21. Epub 2012 Nov 7.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1208958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627494PMC
December 2012

Vemurafenib sensitivity skin reaction after ipilimumab.

N Engl J Med 2012 Mar;366(9):866-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1114329DOI Listing
March 2012

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Invest New Drugs 2011 Oct 27;29(5):1114-21. Epub 2010 Oct 27.

Dermatology Service, Department of Medicine, Rockefeller Outpatient Pavilion, Memorial Sloan-Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9567-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691597PMC
October 2011

Treatment implications of the emerging molecular classification system for melanoma.

Lancet Oncol 2011 Sep 23;12(9):913-22. Epub 2011 Feb 23.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S147020451070274
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(10)70274-6DOI Listing
September 2011

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.

Am J Clin Oncol 2011 Jun;34(3):321-5

Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181e84b1fDOI Listing
June 2011

Therapeutic implications of the emerging molecular biology of uveal melanoma.

Clin Cancer Res 2011 Apr 28;17(8):2087-100. Epub 2011 Mar 28.

Department of Medicine and Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3169DOI Listing
April 2011

Radiotherapy after surgical resection for head and neck mucosal melanoma.

Am J Clin Oncol 2010 Jun;33(3):281-5

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181a879f5DOI Listing
June 2010

Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.

J Clin Oncol 2010 Jun 17;28(18):3042-7. Epub 2010 May 17.

Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.2063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664035PMC
June 2010

Programming T cells for adoptive T cell transfer therapy.

Authors:
Paul B Chapman

Pigment Cell Melanoma Res 2010 Apr 1;23(2):155-6. Epub 2010 Feb 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2010.00681.xDOI Listing
April 2010

The history and future of chemotherapy for melanoma.

Hematol Oncol Clin North Am 2009 Jun;23(3):583-97, x

Melanoma/Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2009.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904102PMC
June 2009

Phase II study of extended-dose temozolomide in patients with melanoma.

J Clin Oncol 2008 May;26(14):2299-304

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.5292DOI Listing
May 2008

Adjuvant therapy of melanoma.

Cancer J 2007 May-Jun;13(3):217-22

Department of Medicine, Melanoma/Sarcoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-200705000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e318074dfd4DOI Listing
January 2008

Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Immunology 2008 Jan;123(1):145-55

Department of Medicine, Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2567.2007.02760.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2433273PMC
January 2008

Melanoma vaccines.

Authors:
Paul B Chapman

Semin Oncol 2007 Dec;34(6):516-23

Melanoma/Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2007.09.013DOI Listing
December 2007

Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.

J Mol Diagn 2007 Apr;9(2):178-83

Department of Dermatology, New York University School of Medicine, 550 First Ave., H-100, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2353/jmoldx.2007.060135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867452PMC
April 2007

When you look matters: the effect of assessment schedule on progression-free survival.

J Natl Cancer Inst 2007 Mar;99(6):428-32

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djk091DOI Listing
March 2007

Immunotherapy of melanoma.

Hematol Oncol Clin North Am 2006 Jun;20(3):751-66

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2006.02.005DOI Listing
June 2006

Variates of survival in metastatic uveal melanoma.

J Clin Oncol 2005 Nov;23(31):8076-80

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.6534DOI Listing
November 2005

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer Chemother Biol Response Modif 2005 ;22:749-60

Department of Medicine & Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
October 2005

Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b.

Oncologist 2005 Oct;10(9):739-42

Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.10-9-739DOI Listing
October 2005